Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1050606020 | 10506060 | 20 | F | 20160501 | 20160825 | 20141008 | 20160831 | EXP | PHHY2012CA020442 | SANDOZ | 68.42 | YR | F | Y | 0.00000 | 20160831 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1050606020 | 10506060 | 1 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 40 MG, QMO (EVERY 4 WEEKS) | U | 0 | 40 | MG | /month | ||||||
| 1050606020 | 10506060 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 50 MG, QMO (EVERY 4 WEEKS) | U | 0 | 50 | MG | /month | ||||||
| 1050606020 | 10506060 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 10 MG, UNK | U | 0 | 10 | MG | |||||||
| 1050606020 | 10506060 | 4 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 40 MG, QMO (EVERY 4 WEEKS) | U | 0 | 40 | MG | /month | ||||||
| 1050606020 | 10506060 | 5 | PS | METOPROLOL. | METOPROLOL | 1 | Oral | U | 73288 | ||||||||||
| 1050606020 | 10506060 | 6 | C | NOVO-BETAHISTINE | 2 | Unknown | 16 MG (1 TABLET), TID | Y | 0 | 16 | MG | TABLET | TID | ||||||
| 1050606020 | 10506060 | 7 | C | NOVO-BETAHISTINE | 2 | Unknown | 16 MG FOLLOWED BY 7 DAYS, BID | Y | 0 | 16 | MG | TABLET | BID | ||||||
| 1050606020 | 10506060 | 8 | C | NOVO-BETAHISTINE | 2 | Unknown | 16 MG (FOR 7 DAYS), QD | Y | 0 | 16 | MG | TABLET | QD | ||||||
| 1050606020 | 10506060 | 9 | C | STATEX | MORPHINE SULFATE | 1 | Unknown | Y | 0 | ||||||||||
| 1050606020 | 10506060 | 10 | C | TAMSULOSIN | TAMSULOSIN | 1 | Unknown | U | 0 | ||||||||||
| 1050606020 | 10506060 | 11 | C | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 1050606020 | 10506060 | 1 | Carcinoid tumour |
| 1050606020 | 10506060 | 5 | Product used for unknown indication |
| 1050606020 | 10506060 | 6 | Product used for unknown indication |
| 1050606020 | 10506060 | 9 | Product used for unknown indication |
| 1050606020 | 10506060 | 10 | Product used for unknown indication |
| 1050606020 | 10506060 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 1050606020 | 10506060 | OT |
| 1050606020 | 10506060 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 1050606020 | 10506060 | Blood pressure increased | |
| 1050606020 | 10506060 | Blood pressure systolic increased | |
| 1050606020 | 10506060 | Contusion | |
| 1050606020 | 10506060 | Diarrhoea | |
| 1050606020 | 10506060 | Dizziness | |
| 1050606020 | 10506060 | Eye movement disorder | |
| 1050606020 | 10506060 | Fall | |
| 1050606020 | 10506060 | Hallucination | |
| 1050606020 | 10506060 | Headache | |
| 1050606020 | 10506060 | Hepatic cancer | |
| 1050606020 | 10506060 | Hot flush | |
| 1050606020 | 10506060 | Nausea | |
| 1050606020 | 10506060 | Nephrolithiasis | |
| 1050606020 | 10506060 | Nightmare | |
| 1050606020 | 10506060 | Photopsia | |
| 1050606020 | 10506060 | Visual field defect |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 1050606020 | 10506060 | 1 | 20090512 | 0 |